ACRS

Aclaris Therapeutics, Inc. focuses on drug discovery and development, specializing in kinase inhibition to create novel small and large molecule drugs for immuno-inflammatory conditions. The company utilizes its proprietary KINect® technology platform to develop kinase inhibitors targeting enzymes involved in chronic inflammation, autoimmune diseases, and cancer. Aclaris also develops biologic therapies, including monoclonal and bispecific antibodies, to address unmet needs in these areas. Additionally, Aclaris operates Confluence Discovery Technologies, Inc., a contract research organization that provides drug discovery and early development services to pharmaceutical and biotech companies.